ADs

ADs is a preclinical-stage multi-specific antibody program being developed by BioSyngen for the treatment of autoimmune disorders. The therapeutic candidate is designed to target and deplete plasma cells, which are the primary source of pathogenic autoantibodies in many autoimmune conditions. By utilizing a multi-specific antibody format, the drug aims to achieve high specificity and potency in eliminating these cells, potentially offering a first-in-class treatment option for patients with various autoimmune diseases. This program represents BioSyngen's expansion of its immunotherapy expertise from oncology into the autoimmune disease space.

Other names

Autoimmune Disorders programBioSyngen multi-specific antibody for autoimmune disorders